1 min read

The Medicines and Related Substances Act, 1965 (Act 101 of 1965) is one of the most important healthcare laws governing the pharmaceutical industry in South Africa. It provides the legal framework for the registration, manufacture, distribution, sale, and monitoring of all health products and related substances across the country.

For pharmaceutical companies planning drug registration in South Africa, understanding this Act is essential to ensure compliance and successful market entry.

What is the Medicines and Related Substances Act, 1965?

Over time, the Act has been updated to reflect global healthcare standards and evolving regulatory requirements.

It now serves as the legal foundation for the South African Health Products Regulatory Authority (SAHPRA), which regulates medicines, medical devices, and related products.

Key Objectives of the Act

The Act is designed to:

  • Ensure the safety, quality, and efficacy of health products
  • Regulate the registration of pharmaceutical products
  • Control manufacturing, import, export, and distribution activities
  • Monitor pricing and access to medicines
  • Prevent the sale of unregistered or unsafe products
  • Support pharmacovigilance and post-market surveillance

Why is Act 101 Important for Pharmaceutical Companies?

Companies seeking to launch medicines in South Africa must comply with this legislation. It impacts:

1. Product Registration

All applicable medicines must be reviewed and approved by the South African Health Products Regulatory Authority before commercialization.

2. Licensing Requirements

Manufacturers, importers, wholesalers, and distributors may require relevant licenses and permits together with other relevant statutory body requirements

3. Labeling and Advertising Compliance

Promotional claims, labeling content, and packaging must follow local regulations.

4. Pricing Controls

The Act introduced frameworks such as the Single Exit Price (SEP) to improve transparency in medicine pricing.

Role of SAHPRA Under the Act

The South African Health Products Regulatory Authority is responsible for implementing the Act and ensuring regulated products meet required standards. SAHPRA reviews applications, conducts inspections, monitors safety signals, and enforces compliance measures.

Common Challenges for Applicants

Companies entering the South African market often face:

  • Complex dossier preparation requirements
  • Delays due to incomplete submissions
  • GMP compliance expectations
  • Labeling adaptation for local rules
  • Post-approval change management obligations

A proactive Regulatory strategy can help reduce approval risks and speed timelines.

Conclusion

The Medicines and Related Substances Act, 1965 (Act 101 of 1965), remains the foundation of pharmaceutical regulation in South Africa. For companies seeking market access, compliance with this law is critical for smooth registrations, legal operations, and long-term success.

Understanding the Act and aligning submissions with SAHPRA expectations can significantly improve your pathway to approval.

Planning to register medicines in South Africa? Freyr Solutions provides end-to-end support for SAHPRA submissions, dossier preparation, lifecycle management, GMP compliance, and market entry strategy. Connect with our experts today to accelerate your South Africa Regulatory success.